Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.
With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.
Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.
Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.
Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.
For more information, visit www.bauschhealth.com.
Bausch Health has announced an agreement to acquire an option to purchase all ophthalmology assets from Allegro Ophthalmics, including global rights to risuteganib, an investigational treatment for dry age-related macular degeneration (AMD). The acquisition is valued at $50 million, with a $10 million initial payment and a contingent $40 million payment expected in 2021. Risuteganib targets multiple pathways involved in AMD, addressing a significant unmet medical need affecting millions globally. The acquisition aligns with Bausch Health's strategy to enhance its pipeline in eye health.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced a presentation by CEO Joseph C. Papa and CFO Paul S. Herendeen at the virtual 18th Annual Morgan Stanley Global Healthcare Conference on Sept. 16, 2020, at 1:15 p.m. ET. The presentation focuses on the company's business recovery post-COVID-19 and updates on its plan to spin off the eye health business. The presentation details are available on Bausch Health's Investor Relations page. Bausch Health aims to enhance global health through its pharmaceutical and medical products.
The Bausch Foundation, overseen by Bausch Health (BHC), released its inaugural activity report detailing philanthropy initiatives from late 2017 to June 30, 2020. The Foundation aims to enhance patient lives globally by providing access to essential medicines and supporting healthcare education. Notably, Bausch Health donated approximately $600 million in pharmaceutical products in 2018 and 2019 to aid financially struggling patients. The Foundation focuses on disease prevention, improving patient outcomes, education, and global relief efforts.
Bausch Health Companies will participate in the 18th Annual Morgan Stanley Global Healthcare Conference on Sept. 16, 2020, at 1:15 p.m. ET. Key executives, including Joseph C. Papa (Chairman and CEO), Sam Eldessouky (SVP), and Arthur J. Shannon (SVP of Investor Relations), will present. Investors can access a live webcast and audio archive on the company’s Investor Relations page. Bausch Health focuses on pharmaceuticals, medical devices, and over-the-counter products, particularly in eye health, gastroenterology, and dermatology.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced on August 31, 2020, a plan to reduce its debt by $100 million through the redemption of senior notes. The company will redeem $100 million of its 5.875% Senior Notes due September 30, 2020, using cash generated from operations. An irrevocable notice of redemption will be issued to the record holders of these notes. Bausch Health aims to strengthen its financial position and continues to focus on advancing global health through its healthcare products.
Bausch Health's subsidiary, Bausch + Lomb, has received approval from Australia's Therapeutic Goods Administration (TGA) for the BAUSCH + LOMB ULTRA® ONE DAY daily disposable silicone hydrogel contact lenses. This product is expected to be available to select practitioners in Australia by Q4 2020, with a nationwide launch planned for early 2021. This approval complements Bausch + Lomb's existing contact lens offerings and aligns with the company’s expansion strategy, which includes launches in Japan and the United States, as well as further expansions in Canada and Hong Kong.
Bausch + Lomb has launched the INFUSE™ silicone hydrogel daily disposable contact lens, designed to combat contact lens dryness affecting about half of U.S. lens wearers. This lens utilizes ProBalance Technology™ to maintain ocular surface homeostasis and retain 96% moisture for 16 hours. The advanced design aims to provide comfort without sacrificing vision correction. Bausch Health Companies Inc. (NYSE/TSX: BHC) emphasizes its commitment to innovative eye care solutions, reflecting the need for advanced materials in contact lens technology.
Bausch Health announced the approval of BAUSCH + LOMB ULTRA® ONE DAY daily disposable silicone hydrogel contact lenses by Health Canada. These lenses incorporate Advanced MoistureSeal® Technology and ComfortFeel Technology, ensuring a high level of comfort and eye health for up to 16 hours. They will be available to select practitioners in Canada starting Q4 2020, with a full launch expected in early 2021. This innovation enhances Bausch + Lomb's existing product portfolio, aiming to improve patient experience in eye care.
Bausch Health reported revenues of $1.664 billion for Q2 2020, a 23% decline from Q2 2019, largely due to the COVID-19 pandemic.
GAAP net loss was $326 million, compared to a $171 million loss in the same quarter last year.
The company has narrowed its full-year revenue guidance to $7.80 - $8.00 billion and Adjusted EBITDA to $3.15 - $3.30 billion.
Despite challenges, Bausch Health is focused on market share growth and launching new products.
Bausch Health Companies Inc. (BHC) announced its plan to spin off its eye health business, creating an independent entity named Bausch + Lomb - NewCo. This strategic move aims to enhance focus on two distinct business segments: a dedicated eye health company and a diversified pharmaceutical firm specializing in gastroenterology, aesthetics/dermatology, and neurology. The spinoff is expected to improve financial transparency and unlock shareholder value. Bausch + Lomb - NewCo reported $3.7 billion in revenue for 2019, while BHC's revenue was $4.9 billion, with plans to report separate financials starting Q1 2021.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
What are the primary areas of focus for Bausch Health?
How many employees does Bausch Health have?
In how many countries does Bausch Health operate?
What is Bausch Health's largest revenue-generating segment?
What recent product development has Bausch Health achieved?
What financial performance did Bausch Health report for Q1 2024?
How is Bausch Health protecting its intellectual property?
Where can I find more information about Bausch Health?
What recent public drug plan listings has Bausch Health achieved in Canada?
Who is the brand ambassador for the XIFAXAN® awareness campaign?
